National Academies Will Meet to Guide 'Gene Editing' Research
By Lisa M. Krieger,
San Jose Mercury News
| 05. 18. 2015
Untitled Document
The debate over human "gene editing" has moved onto the national stage with a prestigious institute announcing it will hold an international summit this fall to create voluntary standards to guide the use of the controversial technology, first conceived by UC Berkeley molecular biologist Jennifer Doudna.
The landmark conference, announced Monday by the Washington, D.C.-based National Academy of Sciences and National Academy of Medicine, will gather researchers and other experts to review and explore the scientific, ethical and social implications of the practice, which can "cut and paste" gene sequences.
Called CRISPR, an acronym for "clustered regularly interspaced short palindromic repeats," Doudna's tool creates the prospect of a future with less sickness -- but could alter future generations -- influencing human evolution by changing the genes in reproductive cells.
The decision to hold a summit follows last month's news that Chinese researchers created the first genetically modified humans, altering nonviable embryos to try to fix the gene defect that causes beta thalassemia, a blood disease.
Doudna and colleagues, including Stanford University bioethicist Hank Greely, last month called for...
Related Articles
By Anna Rogers, Mother Jones | 06.19.2026
By Rebecca Simkin, BioNews | 06.29.2026
The US Food and Drug Administration (FDA) is allowing biotech company Regenxbio to reapply for licensing of a gene therapy for Hunter syndrome, in a reversal of its previous decision. Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is a...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Georgia Michelman, Science | 06.18.2026